SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.During the webcast, Dr. Amit Kumar, Anixa's Chairman and CEO, will conduct an introductory presentation that will cover key aspects of Anixa's business including an overview of the Company's therapeutic portfolio, its busin ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer tr ...

ANIXA BIOSCIENCES INC (ANIX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a chang ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is ANIXA BIOSCIENCES INC (ANIX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.ANIXA BIOSCIENCES INC is a member of our Medical group, which includes 999 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups an ...

收入和利润（同比环比） - 2025年4月30日和2024年4月30日结束的三个月及六个月内公司均无收入[84][92] - 2025年4月30日结束的三个月利息收入从约28.7万美元降至约19万美元，减少约9.6万美元；六个月利息收入从约60.6万美元降至约36.3万美元，减少约24.3万美元[89][97] - 2025年4月30日结束的三个月非控股权益净亏损从约4.1万美元降至约2.3万美元，减少约1.8万美元；六个月非控股权益净亏损从约7.6万美元降至约5.2万美元，减少约2.4万美元[91][98] 成本和费用（同比环比） - 2025年4月30日结束的三个月研发费用从约164.6万美元降至约132.2万美元，减少约32.4万美元；六个月研发费用从约299.5万美元降至约287.4万美元，减少约12.1万美元[86][87][94][95] - 2025年4月30日结束的三个月行政费用从约182.1万美元降至约168.1万美元，减少约14万美元；六个月行政费用从约408.1万美元降至约351.5万美元，减少约56.6万美元[88][96] 其他财务数据 - 2025年4月30日公司流动资产约1676.6万美元，较2024年10月31日的约2136.2万美元减少约459.6万美元[100] - 2025年4月30日结束的六个月经营活动使用现金约440.7万美元，投资活动提供现金约504.5万美元，融资活动提供现金约1000美元，现金及等价物和短期投资从约1992.4万美元降至约1559.7万美元，减少约432.7万美元[101] - 截至2025年4月30日，公司可出售约9700万美元的普通股[100] 管理层讨论和指引 - 公司认为现有现金、现金等价物和短期投资至少能满足未来十二个月的活动资金需求[100] 其他没有覆盖的重要内容 - 公司的收入确认政策要求对合同、交易价格、履约义务等进行判断和估计，相关协议执行时满足履约义务并确认100%收入[103][104][105] - 公司根据管理层对员工时间和精力投入的估计，将某些内部薪酬成本分配到研发费用中[113] - 公司在本报告其他地方的简明合并财务报表附注7中讨论了近期发布声明的影响[115] - 公司管理层对披露控制和程序的设计和运行有效性进行评估，认为截至报告期末这些程序有效[116] - 截至2025年4月30日的三个月内，公司财务报告内部控制没有发生重大影响或可能重大影响的变化[117]

Anixa Biosciences (ANIX) FY 2025 Conference May 20, 2025 11:00 AM ET Speaker0 Alright. For this session, we'll have a presentation, by Anixa Biosciences. Anixa is a clinical stage immuno oncology company with a pipeline of candidates targeting breast cancer and ovarian cancer. Presenting for the company is Mr. Mike Catalani, President, Chief Operating Officer and Chief Financial Officer of of Adnexa. Mike? Speaker1 Thanks, Yi. Thanks, everybody, for being here. And, for those of you listening, webcast now o ...

SAN JOSE, Calif., April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, to be held on May 20, 2025, at Nasdaq World Headquarters in New York City.Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.Details ...

文章核心观点 - 美国专利商标局授予Anixa Biosciences乳腺癌疫苗技术新专利，公司股价周三上涨13%，年初至今涨幅达15.9%，而行业下跌11.4%，公司正与克利夫兰诊所等合作开发多种癌症疫苗，同时还介绍了其他几只同行业排名靠前股票情况 [1][3] 公司专利情况 - 新专利扩大了公司乳腺癌疫苗免疫原性组合物范围，涵盖用含人α - 乳清蛋白免疫原性组合物对患者进行乳腺癌免疫接种方法，该蛋白在某些乳腺癌中表达，是免疫预防策略有前景靶点 [2] - 新专利增强公司知识产权组合，凸显其研究性乳腺癌疫苗独特性，提升公司竞争优势并为候选疫苗及相关技术提供保障，公司在美国和国际市场有多件已授权和待授权专利 [4] 公司疫苗研究进展 - 正在进行的I期研究评估乳腺癌疫苗，确定最大耐受剂量并监测早期三阴性乳腺癌患者免疫反应，数据显示各剂量水平疫苗有抗原特异性免疫反应且安全性良好，公司计划2025年开展该疫苗术前II期研究 [5] - 除乳腺癌疫苗，公司与克利夫兰诊所合作开发一系列治疗和预防卵巢、肺、结肠和前列腺癌疫苗，目前处于临床前或发现阶段 [7] - 公司与莫菲特癌症中心合作开展卵巢癌免疫疗法候选药物I期研究 [9] 公司合作模式 - 创新疫苗技术由克利夫兰诊所开发，已授权给公司，克利夫兰诊所有权从其开发和潜在市场成功中获得特许权使用费和其他商业化收入 [8] 公司评级及相关股票情况 - Anixa Biosciences目前Zacks排名为2（买入） [10] - 拜耳过去30天2025年每股收益预期从1.17美元增至1.19美元，2026年从1.27美元增至1.28美元，年初至今股价上涨17.4%，过去三个季度两次符合预期，一次未达预期，平均负惊喜为19.61% [11] - Dynavax Technologies过去30天2025年和2026年每股收益预期保持不变，分别为33美分和57美分，年初至今股价下跌5.8%，过去四个季度三次超预期，一次未达预期，平均惊喜为9.58% [12] - ADMA Biologics过去30天2025年每股收益预期从70美分增至71美分，2026年保持93美分不变，年初至今股价上涨13.1%，过去四个季度三次超预期，一次未达预期，平均惊喜为32.8% [13]

Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach About Anixa Biosciences, Inc. Contact: SAN JOSE, Calif., April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. The patent alon ...